Effects of Collagen IV on Cisplatin-Induced Apoptosis of Non-Small Cell Lung Cancer Cells

REFERENCES

• Parkin D. M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. C.A. Cancer J. Clin. 2005; 55: 74–108
   PubMed Web of Science ®Google Scholar
• Lilenbaum R. C., Herndon J. E., 2nd, List M. A., et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J. Clin. Oncol. 2005; 23: 190–6
   PubMed Web of Science ®Google Scholar
• D'Addario G., Pintilie M., Leighl N. B., Feld R., Cerny T., Shepherd F. A. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J. Clin. Oncol. 2005; 23: 2926–36
   PubMed Web of Science ®Google Scholar
• Shain K. H., Dalton W. S. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol. Cancer Ther. 2001; 1: 69–78
   PubMed Web of Science ®Google Scholar
• Dalton W. S. The tumor microenvironment as a determinant of drug response and resistance. Drug Resist. Updat. 1999; 2: 285–288
   PubMed Web of Science ®Google Scholar
• Hodkinson P. S., Elliott T., Wong W. S., Rintoul R. C., Mackinnon A. C., Haslett C., et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ. 2006; 13: 1776–88
   PubMed Web of Science ®Google Scholar
• DeClerck Y. A., Mercurio A. M., Stack M. S., Chapman H. A., Zutter M. M., Muschel R. J., et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am. J. Pathol. 2004; 164(4)1131–9
   PubMed Web of Science ®Google Scholar
• Giancotti F. G., Ruoslahti E. Integrin signaling. Science. 1999; 285: 1028–32
   PubMed Web of Science ®Google Scholar
• Damiano J. S., Cress A. E., Hazlehurst L. A., Ahtil A. A., Dalton W. S. Cell adhesion mediated drug resistance (CAM-DR):role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999; 93: 1658–1667
   PubMed Web of Science ®Google Scholar
• Ji-Youn Han, Sug Hong, Kiim Sug Hyung, Lee Won Sang, Park Jung Young, Lee Nam Jin. Yoo. Immunohistochemmical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis. Lung Cancer 2003; 41: 65–70
   PubMed Web of Science ®Google Scholar
• Hopf M., Gohring W., Kohfeldt E., Yamada Y., Timpl R. Recombinant domain IV of perlecan binds to nidogens, laminin± nidogen complex, fibronectin, fibulin-2 and heparin. Eur. J. Biochem. 1999; 259: 917–25
   PubMedGoogle Scholar
• Hallmann R., Horn N., Selg M., Wendler O., Pausch F., Sorokin L. M. Expression and function of laminins in the embryonic and mature vasculature. Physiol. Rev. 2005; 85: 979–1000
   PubMed Web of Science ®Google Scholar
• Sethi T., Rintoul R. C., Moore S. M., MacKinnon A. C., Salter D., Choo C., et al. Extracellular matrix proteins protect small cell lung cancer cells against: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med 1999; 5: 662–668
   PubMed Web of Science ®Google Scholar
• Aoudjit F., Vuori K. Integrin signaling inhibits paclitaexl-induced apoptosis in breast cancer cells. Oncogene 2001; 20: 4995–5004
   PubMed Web of Science ®Google Scholar
• Kammerer U., Kapp M., Gassel A. M., Richter T., Tank C., Dietl J., et al. A new rapid immunohistochemical staining technique using the EnVision antibody complex. J. Histochem. Cytochem. 2001; 49: 623–30
   PubMed Web of Science ®Google Scholar
• Nakahara S., Miyoshi E., Noda K., Ihara S., Gu J., Honke K., et al. Involvement of oligosaccharide changes in alpha5beta1 integrin in a cisplatin-resistant human squamous cell carcinoma cell line. Mol. Cancer Ther. 2003; 2: 1207–1214
   PubMed Web of Science ®Google Scholar
• Elliott T., Sethi T. Integrins and extracellular matrix; a novel mechanism of multidrug resistance. Expert. Rev. Anticancer Ther. 2002; 2: 449–459
   PubMedGoogle Scholar
• Dalton W. S. The tumor microenvironment: focus on myeloma. Cancer Treat Rev. 2003; 29: 11–19, (Suppl.1)
   PubMed Web of Science ®Google Scholar
• Vivanco I., Sawyers C. L. The phosphatidylinositol 3-Kinase AKT pathway in humancancer. Nat. Rev. Cancer. 2002; 2: 489–501
   PubMed Web of Science ®Google Scholar
• Hynes R. O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992; 69: 11–25
   PubMed Web of Science ®Google Scholar
• Scott W. L., Athena W. L. Apoptosis in cancer. Carcinogenesis. 2000; 21: 485–495
   PubMed Web of Science ®Google Scholar
• Diehl J. A., Cheng M., Roussel M. F., Sherr C. J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998; 12: 3499–511
   PubMed Web of Science ®Google Scholar
• Dabholkar M., Reed E. Cisplatin. Cancer Chemother. Biol. Response Modif. 1996; 16: 88–110
   PubMedGoogle Scholar
• Li X., Liu X., Wang J., Wang Z., Jiang W., Reed E., et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res. 2003; 23: 2481–7
   PubMed Web of Science ®Google Scholar
• Jussila L., Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol. Rev. 2002; 82: 673–700
   PubMed Web of Science ®Google Scholar
• Elliott T., Sethi T. Integrins and extracellular matrix; a novel mechanism of multidrug resistance. Expert Rev. Anticancer Ther. 2002; 2: 449–459
   PubMedGoogle Scholar
• Andreas T., Nicolas T. S., Esther T. MCP-1 causes leukocyte recruitment and subsequently endotoxemic ileus in rat. Am. J. Physiol. Gastrointest. Liver Physiol. 2002; 282: G145–55
   PubMed Web of Science ®Google Scholar
• Pinkse G. G., Bouwman W. P., Jiawan-Lalai R., Terpstra O. T., Bruijn J. A., de Heer E. Integrin signaling via RGD peptides and anti-beta1 antibodies confers resistance to apoptosis in islets of Langerhans. Diabetes. 2006; 55: 312–7
   PubMed Web of Science ®Google Scholar
• Tsurutani J., West K. A., Sayyah J., Gills J. J., Dennis P. A. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res. 2005; 65: 8423–32
   PubMed Web of Science ®Google Scholar
• Tsurutani J., West K. A., Sayyah J., Gills J. J. Dennis, PA. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res. 2005; 65: 8423–32
   Google Scholar
• Yu X. R., Jia G. R., Gao G. D., Wang S. H., Han Y., Cao W. Neuroprotection of insulin against oxidative stress-induced apoptosis in cultured retinal neurons: involvement of phosphoinositide 3-kinase/Akt signal pathway. Acta. Biochim. Biophys. Sin. 2006; 38: 241–8
   Google Scholar
• Vanhaesebroeck B., Alessi D. R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 2000; 346: 561–76, Pt 3
   PubMed Web of Science ®Google Scholar